← Back to all trials
Completed
NCT04315558
Revefenacin in Acute Respiratory Insufficiency in COPD
Conditions: COPD, Acute Respiratory Failure
Sex: All
Ages: 40 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 21
Sponsor: University of California, Los Angeles
Location: Ronald Reagan Medical Center at UCLA Los Angeles California
Summary
RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.
Eligibility Criteria
Inclusion Criteria:
* Adults ≥ 40 years of age
* Acute respiratory failure requiring invasive mechanical ventilation
* Documented history of COPD based on spirometric evidence of FEV1/FVC\10 years (current or prior)
* Invasive mechanical ventilation for \< 96 hours
Exclusion Criteria:
* Chronic invasive mechanical ventilation via tracheostomy. Patients with tracheostomy alone without chronic mechanical ventilation may be enrolled.
* Expected duration of mechanical ventilation \
Source: ClinicalTrials.gov (NCT04315558). StuddyBuddy aggregates publicly available trial information.
